Ethics committees

27 February 1992


The report deals with the subject of the patentability of living organisms, excluding as a first step any disc The ICB considers the ethics committees to be an important instrument for the study and promotion of appropriate ethical principles for the exercise of clinical trials and more strictly healthcare. The role played by the ethics committees can concern both the protection of the rights of sick persons, carried out in the respect of professional competences, and the professional training of healthcare staff.

The opinion recommends the setting up of two types of ethics committees, one at a local level and the other at a regional level, with different functions. The local committees should be called upon as a consulting body on the definition of biomedical research protocols, including clinical trials on man, and should be flexible in their composition according to the needs of the healthcare centre and local community. The regional committees should on the other hand work as consultancy organs for the city and regional councils, for all the healthcare initiatives of the region, the regional legislative activity and the administration attaining to the field of assistance and medical research. The analysis of the juridical nature of the ethical committees seems to be of particular importance, which in line of principle can be considered non-recognised associations. The opinion urges for legislation that makes the institution of these bodies obligatory, for the purposes of conferring rationality to the organization of the ethics committees and authority to the opinions expressed by them. For the legislator the possibility is not excluded of foreseeing the creation of ethical committees in the shape of collective administrative bodies, operating in the healthcare management of hospitals or in the scientific direction of research institutes.ussion of the biotechnological inventions having the human body as subject, considered in its whole or in its parts. The idea in fact of patenting the human body in its entirety is considered ethically unacceptable, while the patenting of particular genes or cell lines poses a peculiar problem requiring separate attention.

The Committee takes note that the progress in molecular biology now makes it possible to modify the genetic patrimony of human beings and that the problem arises regarding the protection of the invention of genetically modified organisms. The difference in value is however highlighted existing between living and inanimate organisms and the consequences that this difference entails concerning the subject of patents. In the light of these premises, the interpretative disputes are analysed with regard to the provisions in force and the proposal of the EU directive on the protection of biological inventions presented by the Commission to the Council. According to the Committee, in a first draft the proposal in the directive did not identify the definite limits to the patenting of the living, paying excessive attention to the protection of economic interests of big companies. The second proposal analysed, which acknowledges the observations made by the European Parliament, makes considerable modifications and attempts to combine the interest for patentability to well-defined ethical principles.

The analysis of the juridical and ethical issues of the patenting of the living is carried out by distinguishing between different typologies of inventions, according to whether these have as their subject microorganisms, vegetables or superior animals. With regard to microorganisms, a recommendation is made to better define the juridical notion and to promote actions for the conservation of their biodiversity. As far as concerns the patenting of vegetables, the Committee recommends that excessively rigid solutions are not adopted, derived from the protection of other forms of invention, in order to hold back the activity of industrial biotechnology and avoid the impoverishment of the varieties grown. With regard to the patenting of superior animals, the Committee confirms its bioethical anthropocentric stance and grants the lawfulness of the experimentation and patenting of animals, providing however that well-defined limits are identified, that all procedures for the modification of genetic identity are excluded from patentability which inflict unnecessary suffering to animals, and it recommends that this kind of experimentation be for socially useful purposes.

The report includes a glossary and bibliographical references and concludes with an appendix containing the two drafts of the proposal in the EU directive on the juridical protection of biotechnological inventions, presented by the Commission to the Council.

Torna all'inizio del contenuto